Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Julphar
Farmers Insurance
QuintilesIMS
McKinsey
Fish and Richardson
US Army
Cantor Fitzgerald
Mallinckrodt

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,233,117

« Back to Dashboard

Summary for Patent: 9,233,117
Title:Treatment of inflammatory lesions of rosacea with ivermectin
Abstract: Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.
Inventor(s): Jacovella; Jean (Antibes, FR), Chappuis; Jean-Paul (Valbonne, FR), Sordello Wagner; Nathalie (Pegomas, FR), Graeber; Michael (Lawrenceville, NJ), Kaoukhov; Alexandre (Newport Beach, CA), Salin; Laurence (La Roquette sur Siagne, FR), Poncet; Michel (Mougins, FR), Briantais; Philippe (Antibes, FR), Benkali; Khaled (Antibes, FR)
Assignee: Galderma S. A. (Cham, CH)
Application Number:14/209,927
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,233,117

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp SOOLANTRA ivermectin CREAM;TOPICAL 206255-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,233,117

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,089,587 Treatment of papulopustular rosacea with ivermectin ➤ Subscribe
9,233,118 Treatment of papulopustular rosacea with ivermectin ➤ Subscribe
9,782,425 Treatment of papulopustular rosacea with ivermectin ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,233,117

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2016103753 ➤ Subscribe
Russian Federation 2633076 ➤ Subscribe
Russian Federation 2016103715 ➤ Subscribe
New Zealand 716034 ➤ Subscribe
New Zealand 716033 ➤ Subscribe
Mexico 2016000122 ➤ Subscribe
Mexico 2016000121 ➤ Subscribe
South Korea 20160061311 ➤ Subscribe
South Korea 20160061310 ➤ Subscribe
Japan 2017197562 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
McKesson
Moodys
Teva
Cantor Fitzgerald
Queensland Health
Mallinckrodt
Cipla
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot